CClinicalTrials.gg
Status unknownNCT03290144MUCOGUpdated Sep 25, 2017

Pregnancies and Cystic Fibrosis

An observational study in Cystic Fibrosis, sponsored by Hospices Civils de Lyon. Status unknown. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-25.

Sponsored by Hospices Civils de Lyon · Observational

The sponsor has not verified this record recently (last verified Sep 2017), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
450
Ages
18 Years and older
Sex
Female
01

Study summary

There have been substantial advances in care for individuals with CF, including improved nutrition and respiratory care. Women with CF are now likely to survive into adulthood with a median predicted survival of 49.7 years in 2012, which have resulted in increasingly normal lifestyles, including successful pregnancies in women with CF. The number of pregnancies in CF women has increased as reported by the 2013 Annual Data Report from the French CF Registry (6 pregnancies in 1992 to 53 in 2012). Pregnancy adds many physiological stresses to the body, particularly on pulmonary function (decrease in residual volume, expiratory reserve capacity) and nutritional status (increase in nutritional needs). In women with CF, these added stresses could theoretically affect survival, with difficulties to maintain adequate nutrition and an unpredictable effect on lung function. A number of studies published over the past 15 years have attempted to clarify the risk of pregnancy in women with CF to guide clinicians and women. Many authors compared the outcomes of pregnant CF women to non-pregnant CF women regardless of nutritional status, lung function, diabetes mellitus, bacteriological colonization. In literature, pregnancy was possible and well tolerated in CF women with mild disease if associated with more intensive monitoring and aggressive treatment during pregnancy, with particular emphasis on nutrition and weight gain. CF women have an increased likelihood of receiving treatment for diabetes both during and after pregnancy. Furthermore diabetes mellitus has been associated with more severe pulmonary disease, more frequent pulmonary exacerbations, poorer nutritional status and a reduced life expectancy. Pre-pregnancy diabetes mellitus is associated with a poorer prognosis for pregnancy in general population. Severe forms of CF, including pre-pregnancy diabetes mellitus might as well do badly with accelerated decline after pregnancy. To determine the effect of pre-pregnancy diabetes on maternal decline after pregnancy, we will compare FEV1 and BMI rates of decline, during a two-years follow-up period after pregnancies, reported in the French CF Registry, according to their diabetic status.

02

Conditions studied

  • Cystic Fibrosis

Keywords

  • Cystic fibrosis - Pregnancy - Diabetes
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Study population

All pregnant, Cystic Fibrosis (CF) women attending the CF French Registry between January 1, 2001 and December 31, 2010.

Inclusion criteria

  • Cystic Fibrosis women attending the CF French Registry between January 1, 2001 and December 31, 2010

Exclusion criteria

Exclusion Criteria:

  • Women who had received a pulmonary graft before pregnancy.
04

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
450 participants (actual)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • with diabetes
  • without diabetes
05

What researchers measure

Primary outcomes

  1. Change in FEV1

    Time frame: 12 months following the pregnancy

Secondary outcomes

  1. Change in Body Mass Index (BMI)

    Time frame: 12 months following the pregnancy

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03290144
Lead sponsor
Hospices Civils de Lyon
Responsible party
Sponsor
First posted
Sep 21, 2017
Start date
Feb 2, 2015
Primary completion
Sep 2, 2018 (estimated)
Completion
Sep 2, 2018 (estimated)
Last update
Sep 25, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion